News archive for July 2017
All of our news from July 2017
CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR?
When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be too easy to conclude that one has no frame of reference to help understand what the conclusion will likely be. However, as Harry S Truman said; “There is nothing new in the world except the history you do not know”. There have, of course, been many emerging technologies that have been subject to an IP land-grab. One such instance that we will look at in this article relates to CpG oligonucleotides.Find out more
UK Patent Equivalents, Exclusions and Estoppel – where are we now?
A 5 year battle between Eli Lilly (Lilly) and Actavis centred on Lilly’s patent for the use of pemetrexed disodium for cancer therapy, has culminated in a decision from the UK Supreme Court, allowing Lilly’s appeal and deciding that Actavis' Products directly infringe Eli Lilly's patent in the UK, France, Italy and Spain. The Court also dismissed Actavis' cross-appeal on the basis that if its products did not directly infringe, they would indirectly infringe to the extent held by the Court of Appeal. Full judgment here.Find out more
Crucial Rule Changes for the Patentability of Plants and Animals at the European Patent Office
Starting with immediate effect from the 1st July 2017, plants and animals obtained from essentially biological processes will no longer be patentable before the European Patent Office (EPO).Find out more